Dr Lam (2006) comments on our study Dr Lam (2006) comments on our study (Scott (Scott et al et al, 2006 , 2006a , the largest randomised ), the largest randomised controlled trial (RCT) of psychological controlled trial (RCT) of psychological treatment for bipolar disorder conducted treatment for bipolar disorder conducted so far. We respond as follows. so far. We respond as follows.
(a) (a) Dr Lam seems to misinterpret the nature Dr Lam seems to misinterpret the nature and purpose of pragmatic trials. It is and purpose of pragmatic trials. It is not a matter, as he suggests, simply of not a matter, as he suggests, simply of appropriate outcome measures, which appropriate outcome measures, which should be a feature of all trials. Pragshould be a feature of all trials. Pragmatic trials are intended to test theramatic trials are intended to test therapies in the practical circumstances of pies in the practical circumstances of everyday clinical settings, using large everyday clinical settings, using large multicentre samples (Hotopf multicentre samples (Hotopf et al et al, , 1999) . Most previous trials of therapies 1999). Most previous trials of therapies for bipolar disorders were single-centre for bipolar disorders were single-centre efficacy studies designed to try out new efficacy studies designed to try out new interventions in specialist services or interventions in specialist services or where the originator worked. where the originator worked.
(b) (b) Dr Lam comments on the number of Dr Lam comments on the number of cognitive-behavioural therapy (CBT) cognitive-behavioural therapy (CBT) sessions received. We believe that 20 sessions received. We believe that 20 sessions with 2 boosters is as many as sessions with 2 boosters is as many as is practical in most National Health is practical in most National Health Service (NHS) settings. That patients Service (NHS) settings. That patients attended about 14 of the sessions attended about 14 of the sessions offered is frustrating but reflects clinical offered is frustrating but reflects clinical reality and is remarkably similar to the reality and is remarkably similar to the attendance achieved in Dr Lam's own attendance achieved in Dr Lam's own study (Lam study (Lam et al et al, 2003 (Lam et al et al, : average 13.9 , 2003 : average 13.9 sessions, s.d. sessions, s.d.¼5.5). 5.5).
(c) (c) Our analysis strategy was determined Our analysis strategy was determined before inspection of the data under the before inspection of the data under the scrutiny of a trial steering committee scrutiny of a trial steering committee appointed by the Medical Research appointed by the Medical Research Council. Dr Lam confounds several Council. Dr Lam confounds several issues and recommends an actuarial issues and recommends an actuarial analysis that is fundamentally incorrect analysis that is fundamentally incorrect in the context of an RCT (ICH in the context of an RCT (ICH Harmonised Tripartite Guideline, Harmonised Tripartite Guideline, 1999) . In an intention-to-treat analysis, 1999). In an intention-to-treat analysis, the date of randomisation determines the date of randomisation determines the start of the clock and everyone the start of the clock and everyone who is randomised is analysed; it is who is randomised is analysed; it is wrong to delay the inclusion of any wrong to delay the inclusion of any participant in the analysis until they participant in the analysis until they are asymptomatic. We also reported in are asymptomatic. We also reported in the text on the issue he raised, namely the text on the issue he raised, namely that there was no difference in time to that there was no difference in time to next bipolar episode or mean severity next bipolar episode or mean severity of symptoms in the sample who were of symptoms in the sample who were in acute bipolar episode at baseline, in acute bipolar episode at baseline, not in acute bipolar episode at baseline not in acute bipolar episode at baseline or the whole sample. or the whole sample.
(d) (d) Dr Lam suggests it was inappropriate to
Dr Lam suggests it was inappropriate to include in our study individuals who include in our study individuals who were in a current episode or not on were in a current episode or not on mood stabilisers. However, given that mood stabilisers. However, given that RCTs of therapy for mental disorders RCTs of therapy for mental disorders are usually undertaken with participants are usually undertaken with participants who are currently symptomatic, we who are currently symptomatic, we believe it is important and informative believe it is important and informative to explore the potential effects of to explore the potential effects of therapies commenced in the acute therapies commenced in the acute phase of bipolar disorder. Furthermore, phase of bipolar disorder. Furthermore, in Judd in Judd et al et al's (2002) 12-year follow-up 's (2002) 12-year follow-up it was shown that individuals with it was shown that individuals with bipolar disorder spend 50% of their bipolar disorder spend 50% of their time with syndromal or sub-syndromal time with syndromal or sub-syndromal symptoms of mood disorder, predomisymptoms of mood disorder, predominantly depression. Not receiving or nantly depression. Not receiving or not adhering to recognised mood stabinot adhering to recognised mood stabilisers is a similar well-documented issue lisers is a similar well-documented issue in 20-in 20-50% of individuals with bipolar 50% of individuals with bipolar disorders (Scott & Colom, 2005) . Our disorders (Scott & Colom, 2005) . Our sample thus reflects the realities of clinical sample thus reflects the realities of clinical practice. practice.
(e) (e) It is standard practice in RCTs to
It is standard practice in RCTs to control for design variables and also control for design variables and also to pursue additional analyses that to pursue additional analyses that control for potential confounders control for potential confounders (Schulz & Grimes, 2005) . None of our (Schulz & Grimes, 2005) . None of our analyses failed to converge, a common analyses failed to converge, a common consequence of multi-collinearity. consequence of multi-collinearity.
(f) (f) Dr Lam points out that a median split Dr Lam points out that a median split of a continuous variable can lose inforof a continuous variable can lose information. In fact, this was the reason why mation. In fact, this was the reason why we looked for a trend we looked for a trend across four across four groups as shown in Fig. 4 (p. 318) . groups as shown in Fig. 4 (p. 318) .
Previous studies of psychological theraPrevious studies of psychological therapies have mostly involved more selected popies have mostly involved more selected populations at relatively lower risk of relapse. pulations at relatively lower risk of relapse. In those circumstances CBT appears benefiIn those circumstances CBT appears beneficial. Our study used a mixed patient cial. Our study used a mixed patient sample; many were high-risk or currently sample; many were high-risk or currently symptomatic. We designed the trial in this symptomatic. We designed the trial in this way to address an issue not explored so way to address an issue not explored so far in any other psychological therapy far in any other psychological therapy study, namely whether the treatment would study, namely whether the treatment would be effective in all patients who might be be effective in all patients who might be considered for it. Patients were only exconsidered for it. Patients were only excluded if participation was unfeasible or cluded if participation was unfeasible or unethical. unethical.
Our findings indicate that 22 sessions Our findings indicate that 22 sessions of CBT may not be effective for most of CBT may not be effective for most people seen in NHS general adult psypeople seen in NHS general adult psychiatry settings. In our lower-risk subchiatry settings. In our lower-risk subgroup, similar in characteristics to Dr group, similar in characteristics to Dr Lam's sample (Lam Lam's sample (Lam et al et al, 2003) , CBT , 2003) , CBT may be very helpful. The clinical implicamay be very helpful. The clinical implications are that for a stable, lower-risk poputions are that for a stable, lower-risk population, early in their history of bipolar lation, early in their history of bipolar recurrences, CBT should be considered as recurrences, CBT should be considered as an adjunctive treatment option to further an adjunctive treatment option to further enhance their outcome. For high-risk, comenhance their outcome. For high-risk, complex cases, other forms of therapy should be plex cases, other forms of therapy should be considered, such as those targeted at considered, such as those targeted at medication adherence or relapse prevenmedication adherence or relapse prevention, before considering CBT. These recomtion, before considering CBT. These recommendations are consistent with the results mendations are consistent with the results from published meta-analyses and other from published meta-analyses and other findings on psychological therapies in findings on psychological therapies in bipolar disorders (Scott & Colom, 2005 Although it is encouraging to see the Although it is encouraging to see the Journal Journal take an active role in redressing take an active role in redressing 'editorial racism' as discussed in a 'editorial racism' as discussed in a previous editorial (Tyrer, 2005) , there is a previous editorial (Tyrer, 2005) , there is a need to ensure that promotion of positive need to ensure that promotion of positive discrimination does not exacerbate the discrimination does not exacerbate the problem. problem.
We feel that a recently published ranWe feel that a recently published randomised double-blind placebo-controlled domised double-blind placebo-controlled trial of risperidone performed in India illustrial of risperidone performed in India illustrates the dangers inherent in such a policy trates the dangers inherent in such a policy (Khanna (Khanna et al et al, 2005) . The report had a , 2005). The report had a number of serious shortcomings, which number of serious shortcomings, which included omission of crucial details of the included omission of crucial details of the process of randomisation, interrater reliaprocess of randomisation, interrater reliability and the measures taken to ensure bility and the measures taken to ensure masking. However, the most worrying masking. However, the most worrying aspect of the trial was the use of a placebo aspect of the trial was the use of a placebo in the control group and the apparent in the control group and the apparent absence of any ethical approval to proceed absence of any ethical approval to proceed with this study. What was the justification with this study. What was the justification for denying severely unwell and vulnerable for denying severely unwell and vulnerable patients access to appropriate treatment? patients access to appropriate treatment? Why was there no discussion about the Why was there no discussion about the ethical dilemmas associated with this ethical dilemmas associated with this study? study?
We support the We support the Journal Journal policy of policy of combating editorial racism by promoting combating editorial racism by promoting positive discrimination in the instructions positive discrimination in the instructions to referees. However, the to referees. However, the Journal Journal must must not relinquish its responsibilities as the not relinquish its responsibilities as the official journal of the Royal College of Psyofficial journal of the Royal College of Psychiatrists by failing to act as final arbiter for chiatrists by failing to act as final arbiter for the quality (including the ethics) of the the quality (including the ethics) of the Journal Journal's content.
's content.
With a sample size of 290 patients the With a sample size of 290 patients the report by Khanna report by Khanna et al et al (2005) buttresses (2005) buttresses the data about efficacy of atypical antipsythe data about efficacy of atypical antipsychotics in the treatment of acute mania, chotics in the treatment of acute mania, but the article also raised the following but the article also raised the following concerns. concerns.
One of the sites had to be withdrawn One of the sites had to be withdrawn from the study after enrolling three parfrom the study after enrolling three participants because of concerns about data ticipants because of concerns about data quality. However, the data from these quality. However, the data from these individuals were still included in the safety individuals were still included in the safety analyses. We are of the opinion that if there analyses. We are of the opinion that if there were concerns about the data from one parwere concerns about the data from one particular site, then that site should have been ticular site, then that site should have been excluded from any further analyses. excluded from any further analyses.
We also have concerns about the legitiWe also have concerns about the legitimacy and validity of the informed consent macy and validity of the informed consent obtained from 145 patients with acute obtained from 145 patients with acute mania and a mean Young Mania Rating mania and a mean Young Mania Rating Scale score of 37.5 to be enrolled in the plaScale score of 37.5 to be enrolled in the placebo arm of a clinical trial. Article 4 of the cebo arm of a clinical trial. Article 4 of the World Medical Association Declaration of World Medical Association Declaration of Helsinki Helsinki (World Medical Association, (World Medical Association, 1989) states that biomedical research in-1989) states that biomedical research involving human participants cannot volving human participants cannot legitimately be carried out unless the legitimately be carried out unless the importance of the objective is in proportion importance of the objective is in proportion to the inherent risk to the participant. to the inherent risk to the participant. Delayed treatment of acute mania is asDelayed treatment of acute mania is associated with considerable acute and longsociated with considerable acute and longterm morbidity from both illness and its term morbidity from both illness and its secondary consequences (Post, 2000) . Ransecondary consequences (Post, 2000) . Randomising a patient with acute mania to domising a patient with acute mania to the placebo arm of a 3-week trial leads to the placebo arm of a 3-week trial leads to considerable delay in treatment. considerable delay in treatment.
In this trial 145 patients with acute In this trial 145 patients with acute mania were assigned to the placebo arm. mania were assigned to the placebo arm. We consider it unethical and inhumane to We consider it unethical and inhumane to treat 145 patients with acute mania with treat 145 patients with acute mania with placebo. All future trials concerning the placebo. All future trials concerning the efficacy of a medication for acute mania efficacy of a medication for acute mania should use an arm with one of the proven should use an arm with one of the proven medications as a comparator and not medications as a comparator and not include a placebo arm. include a placebo arm.
Post, R. M. (2000) Post, R. M. (2000 The study was conducted at eight sites in The study was conducted at eight sites in India, as reported in the India, as reported in the Journal Journal article article (page 229); participants were those experi-(page 229); participants were those experiencing an acute exacerbation of symptoms encing an acute exacerbation of symptoms of mania and are described in Table 1 of mania and are described in Table 1 (page 231); adverse events are reported on (page 231); adverse events are reported on pages 232-233; as in all clinical trials, a pages 232-233; as in all clinical trials, a few participants could not be contacted at few participants could not be contacted at follow-up. In this study, 3% of participants follow-up. In this study, 3% of participants were lost to follow-up, which is in line with were lost to follow-up, which is in line with previous studies of mania (Sachs previous studies of mania (Sachs et al et al, , 2002; Yatham 2002; Yatham et al et al, 2003) . , 2003) .
Was the wash-out period medically and morally Was the wash-out period medically and morally justified? justified?
Stable patients who were responsive to Stable patients who were responsive to their current medication were not enrolled their current medication were not enrolled in this trial. Patients who were enrolled in this trial. Patients who were enrolled were symptomatic despite their current were symptomatic despite their current medication (suggesting that they were not medication (suggesting that they were not responsive to the treatment) or because responsive to the treatment) or because they had spontaneously discontinued medithey had spontaneously discontinued medication. In order to successfully assess the cation. In order to successfully assess the trial medication, it was necessary that trial medication, it was necessary that they discontinue their current suboptimally they discontinue their current suboptimally effective medication. This is scientifically effective medication. This is scientifically and ethically justifiable. and ethically justifiable. The trial was conducted in accordance with The trial was conducted in accordance with the principles originating in the Declaration the principles originating in the Declaration of Helsinki. Reference to the 1989 version of Helsinki. Reference to the 1989 version of the document was made since this was of the document was made since this was a commonly cited version at the time the a commonly cited version at the time the study preparations were underway (1999-study preparations were underway (1999) (2000) . 2000). Drs Murtagh and Murphy refer to 'serDrs Murtagh and Murphy refer to 'serious shortcomings' in our report. These are ious shortcomings' in our report. These are said to include omitting crucial details of said to include omitting crucial details of the process of randomisation, interrater the process of randomisation, interrater reliability and masking. In addition, 'the reliability and masking. In addition, 'the most worrying aspect of the trial was the most worrying aspect of the trial was the use of a placebo in the control group and use of a placebo in the control group and apparent absence of any ethical approval apparent absence of any ethical approval to proceed with this study'. to proceed with this study'.
There were no such 'shortcomings' in There were no such 'shortcomings' in the trial itself but not all methods were the trial itself but not all methods were detailed in our report. On page 229, we detailed in our report. On page 229, we wrote, 'Randomisation was stratified by wrote, 'Randomisation was stratified by the presence or absence of psychotic feathe presence or absence of psychotic features at baseline, manic or mixed episode, tures at baseline, manic or mixed episode, and by treatment centre. After randomand by treatment centre. After randomisation and the initiation of treatment isation and the initiation of treatment (baseline), patients remained in hospital (baseline), patients remained in hospital for at least 7 days'. On page 230, we wrote, for at least 7 days'. On page 230, we wrote, 'Investigators were trained in the use of 'Investigators were trained in the use of each of these instruments and certification each of these instruments and certification was required for those administering the was required for those administering the YMRS'. Furthermore, page 229 states, YMRS'. Furthermore, page 229 states, 'Signed informed consent was obtained for 'Signed informed consent was obtained for all participants and the study was conall participants and the study was conducted according to the ducted according to the Recommendations Recommendations Guiding Physicians in Biomedical Research Guiding Physicians in Biomedical Research Involving Human Subjects Involving Human Subjects, in the 1989 ver-, in the 1989 version of the Declaration of Helsinki'. The sion of the Declaration of Helsinki'. The study had the approval of national and study had the approval of national and local research ethics boards. These are local research ethics boards. These are standard descriptions of such procedures standard descriptions of such procedures and are similar to those provided in many and are similar to those provided in many published reports of clinical trials. published reports of clinical trials.
A placebo control was necessary to A placebo control was necessary to establish the effects of medication because establish the effects of medication because people with mania manifest response to people with mania manifest response to placebo which is of variable magnitude. placebo which is of variable magnitude. The true efficacy of risperidone in this trial The true efficacy of risperidone in this trial was incontrovertibly established over and was incontrovertibly established over and above the effects observed with placebo. above the effects observed with placebo.
Similarly, the safety of risperidone can Similarly, the safety of risperidone can only be appropriately assessed in the cononly be appropriately assessed in the context of adverse events in the placebo arm. text of adverse events in the placebo arm. Basil Basil et al et al question why data from a question why data from a site that was withdrawn because of consite that was withdrawn because of concerns about data quality were included in cerns about data quality were included in the safety analyses. It is a conventional the safety analyses. It is a conventional procedure in clinical trials to omit efficacy procedure in clinical trials to omit efficacy data but not safety data from such sites. data but not safety data from such sites. They also question the 'legitimacy' of They also question the 'legitimacy' of the informed consent obtained from the the informed consent obtained from the patients. It is our experience that patients patients. It is our experience that patients with severe illness are capable of giving with severe illness are capable of giving their informed consent to participate in a their informed consent to participate in a trial. Capacity to consent is not automatitrial. Capacity to consent is not automatically lost because of a symptom score on cally lost because of a symptom score on the Young Mania Rating Scale. the Young Mania Rating Scale.
Basil Basil et al et al question the ethics of includquestion the ethics of including a placebo arm in the trial. A placebo ing a placebo arm in the trial. A placebo group was included because patients with group was included because patients with mania generally show a high and variable mania generally show a high and variable placebo response, making it difficult to placebo response, making it difficult to identify their responses to an active identify their responses to an active medication. Placebo-controlled trials are medication. Placebo-controlled trials are valuable in that they expose the fewest valuable in that they expose the fewest patients to potentially ineffective treatpatients to potentially ineffective treatments. In addition, inclusion of a placebo ments. In addition, inclusion of a placebo arm allows a valid evaluation of adverse arm allows a valid evaluation of adverse events attributable to treatment events attributable to treatment v v. those . those independent of treatment. For these reaindependent of treatment. For these reasons, regulatory agencies (Food and Drug sons, regulatory agencies (Food and Drug Administration, European Agency for the Administration, European Agency for the Evaluation of Medicinal Products) and the Evaluation of Medicinal Products) and the consumer associations support the use of consumer associations support the use of placebo controls (Vieta & Carne, 2005) . placebo controls (Vieta & Carné, 2005) .
Most (83%) of the placebo patients Most (83%) of the placebo patients had been receiving treatment for bipolar had been receiving treatment for bipolar disorder for at least 30 days before being disorder for at least 30 days before being hospitalised for the treatment of severe hospitalised for the treatment of severe acute mania. This indicated that their acute mania. This indicated that their current treatments were not adequately current treatments were not adequately treating their symptoms and illness. Thus, treating their symptoms and illness. Thus, as expected, a high response to placebo as expected, a high response to placebo was shown by these patients. Significant was shown by these patients. Significant improvements improvements v v. baseline were seen on each . baseline were seen on each of the efficacy measures in patients of the efficacy measures in patients receiving placebo or risperidone. For examreceiving placebo or risperidone. For example, improvements in YMRS total scores ple, improvements in YMRS total scores at week 3 end-point were at week 3 end-point were 7 710.5 10.5 (s.e. (s.e.¼1.3) in 1.3) in patients receiving placebo patients receiving placebo and and 7 722.7 (s.e. 22.7 (s.e.¼1.1) 1.1) in patients receiving in patients receiving risperidone ( risperidone (P P5 50.001 0.001 v v. baseline in both . baseline in both groups). The proportion of placebo patients groups). The proportion of placebo patients whose severity of illness (Clinical Global whose severity of illness (Clinical Global Impression scale) was rated as 'not ill', Impression scale) was rated as 'not ill', 'mild', or 'very mild' increased from 1% 'mild', or 'very mild' increased from 1% at baseline to over one-third (37%) at at baseline to over one-third (37%) at end-point (the increase was from 0% to end-point (the increase was from 0% to 72% in the risperidone group). 72% in the risperidone group). Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebomonotherapy in bipolar mania: a 3-week placebocontrolled trial followed by a 9-week double-blind trial controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. of risperidone and haloperidol. We thank our correspondents for pointing out an important issue that for pointing out an important issue that we need to address more assiduously in we need to address more assiduously in our reviews of papers. We agree fully that our reviews of papers. We agree fully that the the British Journal of Psychiatry British Journal of Psychiatry needs to needs to ensure that a greater policy of openness ensure that a greater policy of openness towards low-and middle-income countries towards low-and middle-income countries is not accompanied by any lowering of is not accompanied by any lowering of ethical standards. ethical standards.
Declaration of interest
However, there are clear divisions of However, there are clear divisions of opinion here. When the protagonists for opinion here. When the protagonists for each of these make their eloquent argueach of these make their eloquent arguments, it may seem strange that any should ments, it may seem strange that any should remain rather uncomfortably on a rickety remain rather uncomfortably on a rickety fence when the alternative certainties are fence when the alternative certainties are so much more inviting. Well, we are still so much more inviting. Well, we are still wobbling because we feel it is right to wobwobbling because we feel it is right to wobble. The two sides of this argument, put ble. The two sides of this argument, put crudely, are (a) it is unethical to exploit pacrudely, are (a) it is unethical to exploit patients in low-income countries for studies tients in low-income countries for studies that would never be allowed to proceed in that would never be allowed to proceed in rich countries, and (b) research performed rich countries, and (b) research performed for a global scientific community has to for a global scientific community has to provide general evidence, not specific to provide general evidence, not specific to one group or country, and so worldwide efone group or country, and so worldwide efficacy studies are necessary. ficacy studies are necessary.
Drs (2006) also asks whether there is a personal financial aspect to the trial that has been financial aspect to the trial that has been undeclared. The allegation that 'this trial undeclared. The allegation that 'this trial could not have been conducted in a highcould not have been conducted in a highincome country but may have been conincome country but may have been conducted in India because regulatory requireducted in India because regulatory requirements could be fulfilled there' (Srinavasan ments could be fulfilled there' (Srinavasan et al et al) is a serious charge.
) is a serious charge. However, the case for the trial is also However, the case for the trial is also strong. Although strong. Although Basil and his colleagues Basil and his colleagues suggest that 'all future trials concerning suggest that 'all future trials concerning the efficacy of a medication for acute mania the efficacy of a medication for acute mania should use an arm with one of the proven should use an arm with one of the proven medications as a comparator', regulatory medications as a comparator', regulatory bodies such as the Food and Drug Adminisbodies such as the Food and Drug Administration insist on at least two placebotration insist on at least two placebocontrolled studies that demonstrate controlled studies that demonstrate superiority of the index drug over placebo superiority of the index drug over placebo in order to get a licence approved. in order to get a licence approved. Although one may criticise the AdministraAlthough one may criticise the Administration for this requirement, it is scientifically tion for this requirement, it is scientifically unimpeachable and is a general one for unimpeachable and is a general one for drug treatments. A very similar trial has drug treatments. A very similar trial has also been carried out in the USA in which also been carried out in the USA in which risperidone was also compared with risperidone was also compared with placebo treatment (Hirschfeld placebo treatment (Hirschfeld et al et al, 2004) , 2004) (and which should have been disclosed with (and which should have been disclosed with the paper of Khanna the paper of Khanna et al et al, 2005) . The find-, 2005). The findings suggest that when risperidone is ings suggest that when risperidone is licensed for the treatment of mania it is licensed for the treatment of mania it is possible to argue that both these positive possible to argue that both these positive trials represent an advance in patient care. trials represent an advance in patient care. A subsidiary argument, a practical one not A subsidiary argument, a practical one not always well-received in ethical circles, is always well-received in ethical circles, is that participation in a research study can, that participation in a research study can, and should be, a proper and ethical way and should be, a proper and ethical way of providing good patient care, exemplified of providing good patient care, exemplified by the recent comments of Phillips by the recent comments of Phillips et al et al of independence as they do elsewhere, level of independence as they do elsewhere, financial inducements may lead to covert or financial inducements may lead to covert or overt pressures, and there is even sometimes overt pressures, and there is even sometimes a nationalistic element (e.g. if country X a nationalistic element (e.g. if country X can recruit 100 patients, we must not can recruit 100 patients, we must not recruit fewer than 200). This somewhat recruit fewer than 200). This somewhat macho mentality may be behind comments macho mentality may be behind comments such as that by Khanna such as that by Khanna et al et al (2005) that the (2005) that the symptoms of mania in the patients seen symptoms of mania in the patients seen were 'substantially more severe than those were 'substantially more severe than those of patients with bipolar disorder partiof patients with bipolar disorder participating in trials elsewhere', implying that cipating in trials elsewhere', implying that only countries that can be successful in only countries that can be successful in persuading these 'difficult' patients to take persuading these 'difficult' patients to take part should be chosen. part should be chosen.
We note that the Indian Council of We note that the Indian Council of Medical Research has now decided to audit Medical Research has now decided to audit clinical trials systematically to ensure that clinical trials systematically to ensure that national recommendations are followed national recommendations are followed (Mudur, 2005) and the outcome of this will (Mudur, 2005) and the outcome of this will be followed closely. For our part, we have be followed closely. For our part, we have made changes to our refereeing procedure, made changes to our refereeing procedure, and have been asking assessors to examine and have been asking assessors to examine more closely the ethical aspects of papers more closely the ethical aspects of papers that are submitted. We shall also be using that are submitted. We shall also be using our new group of international editors (in our new group of international editors (in the case of India this will be Dr Vikram Pathe case of India this will be Dr Vikram Patel) to advise on ethics both generally and tel) to advise on ethics both generally and with regard to specific papers, attempting with regard to specific papers, attempting as much as possible to take account of the as much as possible to take account of the need for 'autonomy, beneficence, nonneed for 'autonomy, beneficence, nonmaleficence and justice . . (2005) cite the results of clinical trials as evidence supporting their hypothtrials as evidence supporting their hypothesis that the use of antiparkinsonian drugs esis that the use of antiparkinsonian drugs in schizophrenia is an indication of extrain schizophrenia is an indication of extrapyramidal symptoms (EPS). This may be pyramidal symptoms (EPS). This may be true for clinical trials (most of which true for clinical trials (most of which include young adults with no comorbidity) include young adults with no comorbidity) but may not hold true for their observabut may not hold true for their observational study, in which other factors such tional study, in which other factors such as prescribing habits and comorbidity may as prescribing habits and comorbidity may affect the reason for prescription of antiparaffect the reason for prescription of antiparkinsonian drugs. As the mean age of their kinsonian drugs. As the mean age of their sample was 48.6 years, which falls within sample was 48.6 years, which falls within the range in which Parkinson's disease the range in which Parkinson's disease often develops, some patients could have often develops, some patients could have been receiving antiparkinsonian drugs for been receiving antiparkinsonian drugs for the illness the illness per se per se. Although this is . Although this is mentioned as a limitation of the study, it mentioned as a limitation of the study, it has an adverse impact on the central has an adverse impact on the central hypothesis. Since decrements and increhypothesis. Since decrements and increments in antiparkinsonian medication ments in antiparkinsonian medication followed expectations from changes in followed expectations from changes in antipsychotics (Tran antipsychotics (Tran et al et al, 1997) , the results , 1997), the results could well reflect the prescribing pattern of could well reflect the prescribing pattern of the general practitioners (GPs) rather than the general practitioners (GPs) rather than be true evidence for the presence of EPS. be true evidence for the presence of EPS.
One of the main limitations of the study One of the main limitations of the study is the lack of data regarding the reason for is the lack of data regarding the reason for switching antipsychotics. As it is mandaswitching antipsychotics. As it is mandatory to submit data of all major illnesses tory to submit data of all major illnesses (presumably including Parkinson's disease), (presumably including Parkinson's disease), any indication for prescribing or altering any indication for prescribing or altering medication and any adverse drug reaction medication and any adverse drug reaction to the General Practice Research Database to the General Practice Research Database (GPRD; Walley & Mantgani, 1997), the (GPRD; Walley & Mantgani, 1997) , the data could have been provided and would data could have been provided and would have helped in the interpretation of the have helped in the interpretation of the results. Furthermore, during the period results. Furthermore, during the period studied more than 400 GPs provided data studied more than 400 GPs provided data to GPRD but data from only 266 were to GPRD but data from only 266 were analysed. It is not clear why the data from analysed. It is not clear why the data from some GPs were excluded. some GPs were excluded.
Park Park et al et al (2005) classified their study (2005) classified their study population as those switched from typical population as those switched from typical to atypical antipsychotics (TA group) and to atypical antipsychotics (TA group) and those switched from typical to different those switched from typical to different typical antipsychotics (TT group). Howtypical antipsychotics (TT group). However, when we add up the total figures ever, when we add up the total figures provided (3% and 99% were receiving atyprovided (3% and 99% were receiving atypicals and typicals respectively in 1992, picals and typicals respectively in 1992, which changed to 47% and 70% in which changed to 47% and 70% in 2000) , it appears that some patients were 2000), it appears that some patients were receiving a combination of both classes of receiving a combination of both classes of antipsychotics. This could have influenced antipsychotics. This could have influenced the trend for prescribing antiparkinsonian the trend for prescribing antiparkinsonian drugs. drugs.
Park, S., Ross-Degnan, D., Adams, A. S., Park, S., Ross-Degnan, D., Adams, A. S., et al et al ( Authors' reply: We agree with the comWe agree with the comments of Grover & Kulhara on the lack of ments of Grover & Kulhara on the lack of information about the specific reasons for information about the specific reasons for the prescription of antiparkinsonian drugs the prescription of antiparkinsonian drugs in our observational study. We have stated in our observational study. We have stated that such prescribing might have been influthat such prescribing might have been influenced by factors other than the occurrence enced by factors other than the occurrence of EPS. However, previous naturalistic of EPS. However, previous naturalistic studies have shown that the use of antiparstudies have shown that the use of antiparkinsonian medication was highly correlated kinsonian medication was highly correlated with clinical indices of EPS when patients with clinical indices of EPS when patients were prescribed antipsychotics (Barak were prescribed antipsychotics (Barak et et al al, 2002; Bobes , 2002; Bobes et al et al, 2003; Montes , 2003; Montes et al et al, , 2003) . In addition, the sudden change in 2003). In addition, the sudden change in the incidence of antiparkinsonian drug use the incidence of antiparkinsonian drug use following introduction of atypical antipsyfollowing introduction of atypical antipsychotics in the entire population (not just chotics in the entire population (not just among patients who switched type of antiamong patients who switched type of antipsychotic therapy) makes it unlikely that psychotic therapy) makes it unlikely that physician prescribing habits were a strong physician prescribing habits were a strong alternative explanation for our findings. alternative explanation for our findings.
Since we observed the same patients Since we observed the same patients over time in the analysis of drug switching, over time in the analysis of drug switching, changes in antiparkinsonian drug prescribchanges in antiparkinsonian drug prescribing following the switch could be explained ing following the switch could be explained by the differential effects of antipsychotics by the differential effects of antipsychotics on EPS. on EPS.
Nevertheless, antiparkinsonian drug Nevertheless, antiparkinsonian drug prescribing is only a marker of EPS and prescribing is only a marker of EPS and cannot perfectly reflect the incidence of cannot perfectly reflect the incidence of EPS. Owing to the limitation of our data-EPS. Owing to the limitation of our dataset (which did not include indications set (which did not include indications for prescriptions), we cannot exclude the for prescriptions), we cannot exclude the possibility that some patients may have possibility that some patients may have been prescribed antiparkinsonian medibeen prescribed antiparkinsonian medication because they had Parkinson's cation because they had Parkinson's disease, not because they had EPS caused disease, not because they had EPS caused by antipsychotics. by antipsychotics.
Grover & Kulhara question why we Grover & Kulhara question why we included only 266 GPs in this study. We included only 266 GPs in this study. We selected from the GPRD only those patients selected from the GPRD only those patients who had been diagnosed with schizowho had been diagnosed with schizophrenia and prescribed antipsychotics phrenia and prescribed antipsychotics between 1992 and 2000. Therefore 6356 between 1992 and 2000. Therefore 6356 patients who met those requirements and patients who met those requirements and their 266 general practices were included their 266 general practices were included in the study. in the study.
Grover & Kulhara raise the possibility Grover & Kulhara raise the possibility that patients might have taken both that patients might have taken both classes of antipsychotics simultaneously. classes of antipsychotics simultaneously. We examined the effects of switching We examined the effects of switching antipsychotics on antiparkinsonian drug antipsychotics on antiparkinsonian drug prescribing by classifying patients into two prescribing by classifying patients into two groups. We defined the TA group as groups. We defined the TA group as patients who had been prescribed typical patients who had been prescribed typical antipsychotics with no atypical antiantipsychotics with no atypical antipsychotic use before the switch, completely psychotic use before the switch, completely stopped typical antipsychotics and subsestopped typical antipsychotics and subsequently switched to atypical antipsychotics, quently switched to atypical antipsychotics, with no typical antipsychotic use for at least 2 with no typical antipsychotic use for at least 2 years after the switch. The TT group included years after the switch. The TT group included patients who were prescribed one typical patients who were prescribed one typical antipsychotic (e.g. chlorpromazine) then antipsychotic (e.g. chlorpromazine) then switched to a different typical antipsychotic switched to a different typical antipsychotic (e.g. haloperidol), and who never received (e.g. haloperidol), and who never received an atypical antipsychotic during the study an atypical antipsychotic during the study period. Therefore, by definition, no patients period. Therefore, by definition, no patients in our study were receiving a combination in our study were receiving a combination of both classes of antipsychotics. of both classes of antipsychotics. (2006) hypothesise that a more benign course of borderline that a more benign course of borderline personality disorder may partially result personality disorder may partially result from a reduction in iatrogenic harm. They from a reduction in iatrogenic harm. They describe people with borderline personality describe people with borderline personality disorder as having 'hyperactive attachment disorder as having 'hyperactive attachment systems' which interfere with the therasystems' which interfere with the therapeutic relationship and treatment. They peutic relationship and treatment. They describe 'treatment' as being psychosocial describe 'treatment' as being psychosocial treatment or psychotherapy, and attachtreatment or psychotherapy, and attachment figures as therapists. ment figures as therapists.
Many people with borderline personalMany people with borderline personality disorder do not receive psychotherapy ity disorder do not receive psychotherapy but do have contact with psychiatric but do have contact with psychiatric services -casualty assessments, out-patient services -casualty assessments, out-patient contact with generic services, brief crisis contact with generic services, brief crisis admissions and sometimes even prolonged admissions and sometimes even prolonged admissions. I am curious as to Fonagy admissions. I am curious as to Fonagy & Bateman's view on the nature of & Bateman's view on the nature of attachments that people with borderline attachments that people with borderline personality disorder have with psychiatric personality disorder have with psychiatric institutions institutions, especially when contact with , especially when contact with individual workers may be inconsistent. individual workers may be inconsistent. Fonagy & Batemen give advice about how Fonagy & Batemen give advice about how to encourage 'mentalisation' in the context to encourage 'mentalisation' in the context of psychotherapy in order to avoid potenof psychotherapy in order to avoid potential iatrogenic damage but give no advice tial iatrogenic damage but give no advice for other clinical settings. for other clinical settings.
Clinical teams are well aware of Clinical teams are well aware of how people with borderline personality how people with borderline personality disorder may unconsciously 'engineer' disorder may unconsciously 'engineer' situations to re-enact disturbed early life situations to re-enact disturbed early life experiences. Now Fonagy & Bateman experiences. Now Fonagy & Bateman suggest that although teams are aware suggest that although teams are aware of this situation further damage may be of this situation further damage may be done. A 'helpful' intervention may deprive done. A 'helpful' intervention may deprive the patient of using or developing other the patient of using or developing other more useful strategies. Fonagy & Bateman more useful strategies. Fonagy & Bateman suggest that an 'inquisitive and flexible' suggest that an 'inquisitive and flexible' approach may be useful. The challenge is approach may be useful. The challenge is therefore how this approach should be therefore how this approach should be applied to how clinical teams within applied to how clinical teams within instiinstitutions tutions respond to people with borderline respond to people with borderline personality disorder. personality disorder. We share Dr Mountain's concern that this group of patients is often concern that this group of patients is often inadequately managed. Our primary aim inadequately managed. Our primary aim in pointing to the iatrogenic consequences in pointing to the iatrogenic consequences of psychotherapy was to illustrate the danof psychotherapy was to illustrate the dangers of intensive interventions or those with gers of intensive interventions or those with poorly defined boundaries. The same conpoorly defined boundaries. The same concerns for iatrogenic consequences apply to cerns for iatrogenic consequences apply to institutional involvement because this is institutional involvement because this is often disrupted by frequent staff changes. often disrupted by frequent staff changes. Separations and losses of this kind are Separations and losses of this kind are also iatrogenic. They activate patients' also iatrogenic. They activate patients' attachment systems, leading them to make attachment systems, leading them to make unproductive attempts to restabilise their unproductive attempts to restabilise their sense of self. Moreover, interactions with sense of self. Moreover, interactions with institutions often occur at times of personal institutions often occur at times of personal crisis when the attachment system is crisis when the attachment system is already stimulated. Concerns about the already stimulated. Concerns about the patient's state of panic and about reduced patient's state of panic and about reduced mentalising may lead to hospital admission. mentalising may lead to hospital admission. However, this can become iatrogenic in However, this can become iatrogenic in itself because emotionally charged interacitself because emotionally charged interactions with staff and other patients may tions with staff and other patients may further destabilise the patient, leading them further destabilise the patient, leading them to self-harm or threaten suicide, prolonging to self-harm or threaten suicide, prolonging hospital admission. We and others (Paris, hospital admission. We and others (Paris, 2004) recommend that the level of risk 2004) recommend that the level of risk for self-harm of patients admitted to hospifor self-harm of patients admitted to hospital should be assessed and documented tal should be assessed and documented daily. If there is no reduction in risk, alterdaily. If there is no reduction in risk, alternative management of the patient in the native management of the patient in the community should be implemented. community should be implemented.
Although patients may seem to be Although patients may seem to be enacting past experiences in their interacenacting past experiences in their interactions with clinical teams, in our view it tions with clinical teams, in our view it is not useful to consider these as hapless is not useful to consider these as hapless repetition of past patterns or as acts that repetition of past patterns or as acts that respond to or compensate for past hurts; respond to or compensate for past hurts; rather they should be viewed as the only rather they should be viewed as the only solution available to restore a sense of solution available to restore a sense of integrity, continuity and coherence. The integrity, continuity and coherence. The provision of a highly integrated model of provision of a highly integrated model of psychiatric care in a structured institutional psychiatric care in a structured institutional environment that aims to offer consistent, environment that aims to offer consistent, coherent and thoughtful psychological care coherent and thoughtful psychological care with a relationship focus, organised in a with a relationship focus, organised in a patient-oriented flexible manner with indipatient-oriented flexible manner with individualised care plans, is likely to be most vidualised care plans, is likely to be most helpful. Out-patient treatment, discharge helpful. Out-patient treatment, discharge from an in-patient unit or referral following from an in-patient unit or referral following a casualty visit should be considered in a casualty visit should be considered in
